GlobeNewsWire
09 Jun 2026, 12:45 UTC · 2h ago
Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium
GlobeNewsWire
09 Jun 2026, 12:45 UTC · 2h ago
Story key points
3 claims · impact-rated
Palisade Bio is advancing its lead program, PALI-2108, toward Phase 2 clinical studies in ulcerative colitis (UC) and Crohn’s disease. — Progression to Phase 2 is a critical value-inflection point for clinical-stage biotech companies as it tests efficacy in larger patient populations.
+0.40PALI-2108 has demonstrated positive results in a Phase 1a and two Phase 1b clinical trials for UC and fibrostenotic Crohn’s disease (FSCD). — Positive early-phase data reduces technical risk and provides a foundation for the upcoming Phase 2 trials.
+0.30Palisade Bio's CMO will present preclinical findings and the scientific rationale for PALI-2108 at the New York Academy of Sciences symposium. — Conference presentations increase visibility and scientific validation but are generally low-impact unless new data is released.
+0.10Ticker attribution
Continue reading
6 related stories
Top 1 mover · tap to explore
Model heads
The company is presenting promising research on its lead drug candidate at a prestigious scientific symposium.
No ticker relationship head found.
Early access
Unlock the full impact breakdown — and whether these names are in a Stage 2 uptrend right now. Free account, 30 seconds.
No credit card. Cancel anytime.
Browse live screeningsImpact vectors
2 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
GlobeNewsWire
2h ago
